Japanese pharma firms turn to CDMOs early as peptide complexity rises
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Subscribe To Our Newsletter & Stay Updated